Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor

Pharmacogenetics

Volumn 6, Issue 1, 1996, Pages 81-91

  VandenBranden, Mark ^a   Ring, Barbara J ^a   Binkley, Shelly N ^a   Wrighton, Steven A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

human liver microsomes; LY307640; P450s; proton pump inhibitor

Indexed keywords

BUFURALOL; COMPLEMENTARY DNA; COUMARIN; CYTOCHROME P450 ISOENZYME; DESMETHYL LY 307640; DIETHYLDITHIOCARBAMIC ACID; DRUG METABOLITE; ENZYME INHIBITOR; FLUNITRAZEPAM; FURAFYLLINE; LY 307640; LY 307640 SULFONE; MEPHENYTOIN; MIDAZOLAM; OMEPRAZOLE; PHENOBARBITAL; PROTON PUMP INHIBITOR; QUINIDINE; RABEPRAZOLE; SULFAPHENAZOLE; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG METABOLISM; ENZYME KINETICS; HUMAN; HUMAN TISSUE; HYDROXYLATION; LIVER MICROSOME METABOLISM; PRIORITY JOURNAL;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BENZIMIDAZOLES; COUMARINS; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; KINETICS; LIVER; MEPHENYTOIN; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; PROTON-TRANSLOCATING ATPASES; RABBITS; RECOMBINANT PROTEINS; SULFAPHENAZOLE; THEOPHYLLINE;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0029872402     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199602000-00007     Document Type: Article

References (33)

1. Andersson T, Miners JO, Veronese ME, Tassaneeyakul W, Tassaneeyakul W, Meyer UA, Birkett DJ. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993: 36, 521-530.
2. Boxenbaum HG, Riegelman S, Elashoff RM. Statistical estimations in pharmacokinetics. J Pharmacokin and Biopharmacol 1974: 2, 123-148.
3. Broly F, Libersa C, Lhermitte M, Bechtel P, Dupuis B. Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver. Br J Clin Pharmacol 1989: 28, 29-36.
4. Chiba K, Kabayashi K, Manabe K, Tani M, Kamataki T, Ishizaki T. Oxidative metabolism of omeprazole in human liver microsomes: Cosegregation with S-mephenytoin 4′-hydroxylation. Pharmacol Exp Ther 1993: 266, 52-59.
5. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker J, Ghanayem BI. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994: 33, 1743-1752.
6. Gorski JC, Jones DR, Wrighton SA, Hall SD. Characterization of dextromethorphan N-demethylation by human liver microsomes. Biochem Pharmacol 1994: 47, 173-182.
7. Guengerich FP, Muller-Enoch D, Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol 1986: 30, 287-295.
8. Guengerich FP, Kim D-H, Iwasaki M. Role of human cytochrome P450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 1991: 4, 168-179.
9. Hall SD, Hamman MA, Rettie AE, Wienkers LC, Trager WF, VandenBranden M, Wrighton SA. Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes. Drug Metab Disp 1994: 22, 975-978.
10. Houston JB. Relevance of in vitro kinetic parameters to in vivo metabolism of xenobiotics. Toxicol In Vitro 1994a: 8, 507-512.
11. Houston JB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 1994b: 47, 1469-1479.
12. Ishizaki T, Chiba K, Manabe K, Koyama E, Hayashi M, Yasuda S, Horai Y, Tomono Y, Yamato C, Toyoki T. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation. Clin Pharmacol Ther 1995: 58, 155-164.
13. Lowry OH, Rosebrough RJ, Farr AL, Randall RJ. Protein determination with the Folin phenol reagent. J Biol Chem 1951: 193, 265-275.
14. Massoomi F, Savage J, Destache CJ. Omeprazole: A comprehensive review. Pharmacotherapy 1993: 13, 46-59.
15. Peck CC, Temple R, Collins JM. Understanding consequences of concurrent therapies. JAMA 1993: 269, 1550-1552.
16. Pessayre D, Tinel M, Larrey D, Colbert B, Funck-Bretano C, Babany G. Inactivation of cytochrome P-450 by a troleandomycin metabolite: Protective role of glutathione. J Pharmacol Exp Ther 1983: 224, 685-691.
17. Regardh GG, Andersson T, Lagerstrom PO, Lundborg P, Skanberg I. The pharmacokinetics of omeprazole in humans - a study of single intravenous and oral doses. Ther Drug Monit 1990: 12, 163-172.
18. Segel IH. Enzyme Kinetics: Behavior and analysis of rapid equilibrium and steady-state enzyme systems. New York, NY: John Wiley and Sons, 1975.
19. Sesardic D, Boobis AR, Murray BP, Murray S, Segura J, De La Torre R, Davies DS. Furafylline is a potent and selective inhibitor of cytochrome P450IA2. Br J Clin Pharmacol 1991: 29, 651-662.
20. Skjelbo E, Brosen K. Inhibitors of imiprimine metabolism by human liver microsomes. Br J Clin Pharmacol 1992: 34, 256-261.
21. Smith DA, Jones BC. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol 1992: 44, 2089-2098.
22. Stevens JC, Wrighton SA. Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. J Pharmacol Exp Ther 1993: 266, 964-971.
23. Tucker GT. The rational selection of drug interaction studies: Implications of recent advances in drug metabolism. Internat J Clin Pharmacol Ther Toxicol 1992: 30, 550-553.
24. van der Hoeven TA, Coon MJ. Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes. J Biol Chem 1974: 249, 6302-6310.
25. Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO, Birkett DJ. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun 1991: 175, 1112-1118.
26. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992: 22, 1-21.
27. Wrighton SA, Ring BJ. Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharmaceut Res 1994: 11, 921-924.
28. Wrighton SA, Brian WR, Sari M-A, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, VandenBranden M. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Molec Pharmacol 1990: 38, 207-213.
29. Wrighton SA, Stevens JC, Becker GW, VandenBranden M. Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 1993a: 306, 240-245.
30. Wrighton SA, VandenBranden M, Stevens JC, Shipley LA, Ring BJ, Rettie AE, Cashman JR. In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab Rev 1993b: 25, 453-484.
31. Yasuda S, Ohnishi A, Ogawa T, Tomono Y, Hasegawa J, Nakai H, Shimamura Y, Morishita N. Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. Internat J Clin Pharmacol Ther Toxicol 1994: 32, 466-473.
32. Yasuda S, Horai Y, Tomono Y, Nakai H, Yamato C, Manabe K, Kobayashi K, Chiba K, Ishizaki T. Comparison of the kinetic disposition and metabolism of a new proton pump inhibitor, E3810, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clin Pharmacol Ther 1995: 58, 143-154.
33. Yun C-H, Shimada T, Guengerich FP. Purification and characterization of human liver microsomal cytochrome P-450 2A6. Molec Pharmacol 1991: 40, 679-685.